stoxline Quote Chart Rank Option Currency Glossary
  
Immix Biopharma, Inc. (IMMX)
1.64  0.07 (4.46%)    04-17 16:00
Open: 1.6
High: 1.67
Volume: 16,519
  
Pre. Close: 1.57
Low: 1.61
Market Cap: 45(M)
Technical analysis
2025-04-17 4:49:55 PM
Short term     
Mid term     
Targets 6-month :  2.08 1-year :  2.4
Resists First :  1.78 Second :  2.05
Pivot price 1.57
Supports First :  1.34 Second :  1.11
MAs MA(5) :  1.61 MA(20) :  1.63
MA(100) :  1.91 MA(250) :  1.94
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  58.9 D(3) :  54.9
RSI RSI(14): 49.7
52-week High :  2.71 Low :  1.25
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IMMX ] has closed below upper band by 33.2%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.67 - 1.68 1.68 - 1.68
Low: 1.59 - 1.6 1.6 - 1.61
Close: 1.63 - 1.64 1.64 - 1.65
Company Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Headline News

Thu, 27 Mar 2025
Immix Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView

Sat, 08 Mar 2025
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - simplywall.st

Mon, 10 Feb 2025
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis - GlobeNewswire

Thu, 19 Dec 2024
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - GlobeNewswire

Tue, 10 Dec 2024
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - GlobeNewswire

Tue, 10 Dec 2024
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 28 (M)
Shares Float 18 (M)
Held by Insiders 39.7 (%)
Held by Institutions 12.1 (%)
Shares Short 367 (K)
Shares Short P.Month 389 (K)
Stock Financials
EPS -0.76
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.47
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -66.2 %
Return on Equity (ttm) -147.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.82
Qtrly Earnings Growth 0 %
Operating Cash Flow -15 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -2.16
PEG Ratio 0
Price to Book value 3.41
Price to Sales 0
Price to Cash Flow -3.12
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android